Menactra Pricing Will Be In Line With Wyeth's Prevnar, Sanofi-Aventis Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi-Aventis will price its meningococcal conjugate vaccine Menactra in line with Wyeth's pneumococcal vaccine Prevnar
You may also be interested in...
Menactra Launch Slated For March On Heels Of Broad CDC Recommendations
Advisory Committee on Immunization Practices recommends routine meningococcal vaccination for adolescents ages 11-12, those entering high school and college freshmen living in dorms. Panel acknowledges that broad recommendations could lead to supply constraints, Sanofi says.
Menactra Launch Slated For March On Heels Of Broad CDC Recommendations
Advisory Committee on Immunization Practices recommends routine meningococcal vaccination for adolescents ages 11-12, those entering high school and college freshmen living in dorms. Panel acknowledges that broad recommendations could lead to supply constraints, Sanofi says.
Sanofi-Aventis Eyes Expanded Menactra Indication Following Initial Approval
FDA approves the meningococcal conjugate vaccine for patients 11-55 years old; Sanofi-Aventis will submit a sBLA for use in children ages 2-11 by February. The company is currently studying the vaccine in patients under age 2 and will initiate a study evaluating Menactra in subjects over age 55 years by January 2006.